MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2024.126241

Медицинская библиотека · Vaccine · 2024

Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.

Shinjoh Masayoshi, Yaginuma Mizuki, Yamaguchi Yoshio, Tamura Kazuyo, Furuichi Munehiro, Tsumura Yuki, Itaki Ryo, Iqbal Asef, Maeda Naonori, Narabayashi Atsushi, Kamei Akinobu, Shibata Akimichi, Yamada Go, Nishida Mitsuhiro, Kenichiro Tsunematsu, Chiga Michiko, Shimoyamada Motoko, Yoshida Makoto, Fukushima Naoya, Nakata Yuji, Fukushima Hiroyuki, Kawakami Chiharu, Narumi Satoshi, Sugaya Norio, Keio Pediatric Influenza Research Group

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The annual administration of the influenza vaccine is the most effective method for preventing influenza. We have evaluated the effectiveness of the inactivated influenza vaccine in children aged 6 months to 15 years across the seasons from 2013/2014 to 2022/2023. This study aims to investigate the effectiveness of the inactivated influenza vaccine in the 2023/2024 season, the first year following the easing of strict COVID-19 measures, and possibly the last season when only the inactivated vaccine is available on the market.

METHODS

Adjusted vaccine effectiveness for the 2023/2024 season was assessed using a test-negative case-control design, with results based on polymerase chain reaction and rapid influenza diagnostic tests. Vaccine effectiveness was calculated by influenza type and patient hospitalization/outpatient status.

RESULTS

A total of 1832 children were recruited. The inactivated influenza vaccine was effective in preventing both symptomatic influenza A and B in both inpatient and outpatient settings. Overall vaccine effectiveness for influenza A was 51% (95% confidence interval [CI], 23%-69%, n = 930) in inpatient settings and 54% (95%CI, 27%-71%, n = 559) in outpatient settings. For influenza B, effectiveness was 60% (95%CI, 22%-79%, n = 859) in inpatient settings and 56% (95%CI, 26%-74%, n = 558) in outpatient settings. Analysis suggested that administering two doses enhanced effectiveness specifically against influenza B.

CONCLUSIONS

This is the first study to demonstrate influenza vaccine effectiveness in children after the relaxation of strict COVID-19 measures in Japan (2023/2024). We recommend the current inactivated vaccine for preventing both influenza A and B in children, with consideration for the potential use of two doses to enhance effectiveness against influenza B.

Для цитирования: Shinjoh Masayoshi, Yaginuma Mizuki, Yamaguchi Yoshio, Tamura Kazuyo, Furuichi Munehiro, Tsumura Yuki, Itaki Ryo, Iqbal Asef, Maeda Naonori, Narabayashi Atsushi, Kamei Akinobu, Shibata Akimichi, Yamada Go, Nishida Mitsuhiro, Kenichiro Tsunematsu, Chiga Michiko, Shimoyamada Motoko, Yoshida Makoto, Fukushima Naoya, Nakata Yuji, Fukushima Hiroyuki, Kawakami Chiharu, Narumi Satoshi, Sugaya Norio, Keio Pediatric Influenza Research Group. Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.. Vaccine. 2024. DOI: 10.1016/j.vaccine.2024.126241.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.